Pfizer Inc (PFE) 30.07 $PFE
Johnson & Johnson Prescribes Healthy Returns Without M&A or Breakup
at The Street - Sun Jul 13, 7:32PM CDT
'Bigger' only for the sake of getting bigger makes no sense. Not trusting management of the company to execute the business is the worst blunder of them all.
Tax Inversions: Why Are They So Popular?
Dan Caplinger, The Motley Fool - Motley Fool - Sun Jul 13, 7:05AM CDT
Recently, Medtronic and Covidien became the latest pair of companies to consider a high-value merger. One of the big motivations for these international mergers is the opportunity to do a tax inversion. But what exactly is a tax inversion, and...
Abbott, Nestle, Prepare to Profit from China���s Upcoming Baby Boom
at The Street - Fri Jul 11, 1:44PM CDT
The one-child policy has been relaxed, giving makers of baby formula and incubators more opportunities to make money
Midday Glance: Pharmaceuticals companies
AP - Fri Jul 11, 12:38PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Fri Jul 11, 9:30AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Most active New York Stock Exchange-traded stocks
AP - Thu Jul 10, 12:44PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
'Mad Money' Lightning Round: AT&T Is a Buy
at The Street - Thu Jul 10, 5:00AM CDT
Cramer wants to own WhiteWave Foods, likes Johnson & Johnson over Pfizer and wants you to stay away from Gogo.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
AbbVie Boosts Offer for UK-Based Shire Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 3:30PM CDT
AbbVie Inc. (ABBV) continues to pursue Shire (SHPG) and has now come up with a fourth proposal.
Who pays your doc? Coming soon to a site near you
By MATTHEW PERRONE - AP - Wed Jul 09, 1:18PM CDT
WASHINGTON (AP) — When many of us have a medical appointment we're concerned about our finances: how much will we owe out-of-pocket? What's our co-pay? But next time, you may also want to ask your doctors about their financial situation.
Dow Today: American Express (AXP) Leads The Day Higher, Pfizer (PFE) Lags
at The Street - Wed Jul 09, 9:00AM CDT
The Dow component leading the way higher looks to be American Express (NYSE: AXP ), which is sporting a 92-cent gain (+1%) bringing the stock to $95.23. Holding back the Dow today is Pfizer (NYSE: PFE ), which is lagging the broader Dow index...
What RXi Pharmaceuticals' Move to the Russell Microcap Index Means
ACCESSWIRE - Wed Jul 09, 8:48AM CDT
WHITEFISH, MT / July 9, 2014 / RXi Pharmaceuticals Corp. (NASDAQ: RXII), a biotechnology company focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently began trading on the Russell Microcap index on June 27, 2014. Membership on the index remains for one year and is based on market cap and style attributes.
Better Buy: Clovis Oncology vs. Sunesis Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 4:00PM CDT
Oncology has long been one of the most active areas in pharmaceutical research, because new drugs tend to have high profit margins and long shelf lives and are often amenable to broad label expansions for a diversity of cancer types. Clovis...
The Internet Is Brutally Efficient and Totally Agnostic
at The Street - Tue Jul 08, 1:10PM CDT
Investors should remove their emotion when thinking of the Internet.
Global Contraceptives Market 2014-2018 with Actavis, Bayer AG, J&J's, Janssen Pharma, Merck & Co., Pfizer, & Teva Pharmaceutical Leading the Way
M2 - Tue Jul 08, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d964b9/global) has announced the addition of the "Global Contraceptives Market 2014-2018" report to their offering. The global contraceptives market is set to grow at a CAGR of 5.90 percent over the period 2013-2018. The Global Contraceptives market is driven by several factors, of which the growing prevalence of unplanned pregnancies is one of the major drivers. In order to control the 41 percent of unplanned pregnancies out of 208.2 million pregnancies globally, there has been an increase in the number of initiatives by governments and NGOs. Furthermore, the report states that one of the major challenges is the introduction of low-cost generic contraceptives. Recently, pharmaceutical companies have introduced new products into their portfolios or diversified their contraceptive drugs and devices. This trend has been primarily supported by several prominent deals or partnerships to develop or introduce new products with better efficacy and safety profiles. These strategic decisions will help companies to generate revenue and acquire a significant share of the Global Contraceptives market. Some of the major acquisitions in this space include Conceptus Inc. by Bayer, Warner Chilcott plc by Actavis, Uteron Pharma SA by Watson Pharmaceuticals Inc., and Barr Pharmaceuticals Inc. by Teva Pharmaceutical Industries. Some of the other prominent deals include Bayer and USAID partnering to make Microgynon, an oral contraceptive and Starpharma Holdings licensing agreement with Okamoto Industries Inc. for the VivaGel-coated condom. The global contraceptives market can be segmented broadly into two divisions: Drugs and Devices. This report covers the present scenario and the growth prospects of the Global Contraceptives market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for contraception which include: - Drugs (Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives) - Devices (Male & Female condoms, Diaphragms, IUDs, Vaginal Rings, Female Sponges and Subdermal Contraceptive Implants) Key Vendors: - Actavis plc - Bayer AG - Johnson & Johnson's Janssen Pharmaceuticals, Inc. - Merck & Co. - Pfizer, Inc. - Teva Pharmaceutical Industries, Ltd Other Prominent Vendors: - Adamis Pharmaceuticals Corp. - Agile Therapeutics, Inc. - ANI Pharmaceuticals, Inc. - Ansell Ltd. - Apothecus Pharmaceutical Corp. - Blairex Laboratories Inc. - Church & Dwight, Co. Inc. - Caldwell Consumer Health, LLC. - Ferring International Center S.A - Fuji Latex Co., Ltd. - HLL Lifecare Limited - Mayer Laboratories - Medicines 360 - Karex Berhad - Lipocine Inc. - Lupin Pharmaceuticals, Inc. - Mylan Laboratories Inc. - Okamoto Industries, Inc. - Pantarhei Bioscience B.V. - Paul Hartmann AG - Reckitt Benckiser Group Plc - The Female Health Company For more information visit http://www.researchandmarkets.com/research/d964b9/global
Cognitive Impairment Associated With Schizophrenia (CIAS) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 10:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/85qd7j/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" report to their offering. Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" provides data on the Cognitive Impairment Associated With Schizophrenia (CIAS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cognitive Impairment Associated With Schizophrenia (CIAS). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cognitive Impairment Associated With Schizophrenia (CIAS). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - Novartis AG - Merck & Co., Inc. - AbbVie Inc. - Takeda Pharmaceutical Company Limited - Saniona AB - Johnson & Johnson - GlaxoSmithKline plc - VA Greater Los Angeles Healthcare Center - Hamamatsu University School of Medicine - Bronx Veterans Medical Research Foundation - Mashhad University of Medical Sciences - St. Marianna University School of Medicine - Yale University - Indiana University - Central South University - University of Southern Denmark - Northwestern University For more information visit http://www.researchandmarkets.com/research/85qd7j/cognitive
Johnson & Johnson Prescribes Healthy Returns Without M&A or Breakup
at The Street - Sun Jul 13, 7:32PM CDT
'Bigger' only for the sake of getting bigger makes no sense. Not trusting management of the company to execute the business is the worst blunder of them all.
Tax Inversions: Why Are They So Popular?
Dan Caplinger, The Motley Fool - Motley Fool - Sun Jul 13, 7:05AM CDT
Recently, Medtronic and Covidien became the latest pair of companies to consider a high-value merger. One of the big motivations for these international mergers is the opportunity to do a tax inversion. But what exactly is a tax inversion, and...
Abbott, Nestle, Prepare to Profit from China���s Upcoming Baby Boom
at The Street - Fri Jul 11, 1:44PM CDT
The one-child policy has been relaxed, giving makers of baby formula and incubators more opportunities to make money
Midday Glance: Pharmaceuticals companies
AP - Fri Jul 11, 12:38PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Fri Jul 11, 9:30AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Most active New York Stock Exchange-traded stocks
AP - Thu Jul 10, 12:44PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
'Mad Money' Lightning Round: AT&T Is a Buy
at The Street - Thu Jul 10, 5:00AM CDT
Cramer wants to own WhiteWave Foods, likes Johnson & Johnson over Pfizer and wants you to stay away from Gogo.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
AbbVie Boosts Offer for UK-Based Shire Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 3:30PM CDT
AbbVie Inc. (ABBV) continues to pursue Shire (SHPG) and has now come up with a fourth proposal.
Who pays your doc? Coming soon to a site near you
By MATTHEW PERRONE - AP - Wed Jul 09, 1:18PM CDT
WASHINGTON (AP) — When many of us have a medical appointment we're concerned about our finances: how much will we owe out-of-pocket? What's our co-pay? But next time, you may also want to ask your doctors about their financial situation.
Dow Today: American Express (AXP) Leads The Day Higher, Pfizer (PFE) Lags
at The Street - Wed Jul 09, 9:00AM CDT
The Dow component leading the way higher looks to be American Express (NYSE: AXP ), which is sporting a 92-cent gain (+1%) bringing the stock to $95.23. Holding back the Dow today is Pfizer (NYSE: PFE ), which is lagging the broader Dow index...
What RXi Pharmaceuticals' Move to the Russell Microcap Index Means
ACCESSWIRE - Wed Jul 09, 8:48AM CDT
WHITEFISH, MT / July 9, 2014 / RXi Pharmaceuticals Corp. (NASDAQ: RXII), a biotechnology company focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently began trading on the Russell Microcap index on June 27, 2014. Membership on the index remains for one year and is based on market cap and style attributes.
Better Buy: Clovis Oncology vs. Sunesis Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 4:00PM CDT
Oncology has long been one of the most active areas in pharmaceutical research, because new drugs tend to have high profit margins and long shelf lives and are often amenable to broad label expansions for a diversity of cancer types. Clovis...
The Internet Is Brutally Efficient and Totally Agnostic
at The Street - Tue Jul 08, 1:10PM CDT
Investors should remove their emotion when thinking of the Internet.
Global Contraceptives Market 2014-2018 with Actavis, Bayer AG, J&J's, Janssen Pharma, Merck & Co., Pfizer, & Teva Pharmaceutical Leading the Way
M2 - Tue Jul 08, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d964b9/global) has announced the addition of the "Global Contraceptives Market 2014-2018" report to their offering. The global contraceptives market is set to grow at a CAGR of 5.90 percent over the period 2013-2018. The Global Contraceptives market is driven by several factors, of which the growing prevalence of unplanned pregnancies is one of the major drivers. In order to control the 41 percent of unplanned pregnancies out of 208.2 million pregnancies globally, there has been an increase in the number of initiatives by governments and NGOs. Furthermore, the report states that one of the major challenges is the introduction of low-cost generic contraceptives. Recently, pharmaceutical companies have introduced new products into their portfolios or diversified their contraceptive drugs and devices. This trend has been primarily supported by several prominent deals or partnerships to develop or introduce new products with better efficacy and safety profiles. These strategic decisions will help companies to generate revenue and acquire a significant share of the Global Contraceptives market. Some of the major acquisitions in this space include Conceptus Inc. by Bayer, Warner Chilcott plc by Actavis, Uteron Pharma SA by Watson Pharmaceuticals Inc., and Barr Pharmaceuticals Inc. by Teva Pharmaceutical Industries. Some of the other prominent deals include Bayer and USAID partnering to make Microgynon, an oral contraceptive and Starpharma Holdings licensing agreement with Okamoto Industries Inc. for the VivaGel-coated condom. The global contraceptives market can be segmented broadly into two divisions: Drugs and Devices. This report covers the present scenario and the growth prospects of the Global Contraceptives market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for contraception which include: - Drugs (Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives) - Devices (Male & Female condoms, Diaphragms, IUDs, Vaginal Rings, Female Sponges and Subdermal Contraceptive Implants) Key Vendors: - Actavis plc - Bayer AG - Johnson & Johnson's Janssen Pharmaceuticals, Inc. - Merck & Co. - Pfizer, Inc. - Teva Pharmaceutical Industries, Ltd Other Prominent Vendors: - Adamis Pharmaceuticals Corp. - Agile Therapeutics, Inc. - ANI Pharmaceuticals, Inc. - Ansell Ltd. - Apothecus Pharmaceutical Corp. - Blairex Laboratories Inc. - Church & Dwight, Co. Inc. - Caldwell Consumer Health, LLC. - Ferring International Center S.A - Fuji Latex Co., Ltd. - HLL Lifecare Limited - Mayer Laboratories - Medicines 360 - Karex Berhad - Lipocine Inc. - Lupin Pharmaceuticals, Inc. - Mylan Laboratories Inc. - Okamoto Industries, Inc. - Pantarhei Bioscience B.V. - Paul Hartmann AG - Reckitt Benckiser Group Plc - The Female Health Company For more information visit http://www.researchandmarkets.com/research/d964b9/global
Cognitive Impairment Associated With Schizophrenia (CIAS) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 10:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/85qd7j/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" report to their offering. Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" provides data on the Cognitive Impairment Associated With Schizophrenia (CIAS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cognitive Impairment Associated With Schizophrenia (CIAS). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cognitive Impairment Associated With Schizophrenia (CIAS). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - Novartis AG - Merck & Co., Inc. - AbbVie Inc. - Takeda Pharmaceutical Company Limited - Saniona AB - Johnson & Johnson - GlaxoSmithKline plc - VA Greater Los Angeles Healthcare Center - Hamamatsu University School of Medicine - Bronx Veterans Medical Research Foundation - Mashhad University of Medical Sciences - St. Marianna University School of Medicine - Yale University - Indiana University - Central South University - University of Southern Denmark - Northwestern University For more information visit http://www.researchandmarkets.com/research/85qd7j/cognitive
